Skip to Content

Catalent Inc

View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation

Narrow-Moat Catalent Remains on Track To Be Acquired by Novo Nordisk to Expand Wegovy Manufacturing

Business Strategy and Outlook

Catalent is a leading contract development and manufacturing organization, or CDMO. The company has an extensive network of partnerships with pharmaceutical and biotechnology firms that leverage its expertise and scale to optimize drug production and avoid the risks of in-house drug manufacturing. The challenges and compliance risks associated with changing a drug’s manufacturing process create a sticky relationship for Catalent’s customers. Drug companies tend to stick with trusted suppliers with good track records of regulatory compliance, which makes them unlikely to switch to a different CDMO.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CTLT so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center